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Abstract
Background: The objective of this study was to investigate the distribution and susceptibility of aerobic and
facultative Gram-negative bacilli isolated from Chinese patients with UTIs collected within 48 h (community
acquired, CA) or after 48 h (hospital acquired, HA) of hospital admission.
Methods: From 2010 to 2014, the minimum inhibitory concentrations (MICs) of 12 antibiotics for 4,332 aerobic and
facultative Gram-negative bacilli, sampled in 21 hospitals in 16 cities, were determined by the broth microdilution
method.
Results: Enterobacteriaceae composed 88.5% of the total isolates, with Escherichia coli (E. coli) (63.2%) the most
commonly isolated species, followed by Klebsiella pneumoniae (K. pneumoniae) (12.2%). Non-Enterobacteriaceae
accounted for only 11.5% of all isolates and included mainly Pseudomonas aeruginosa (P. aeruginosa) (6.9%) and
Acinetobacter baumannii (A. baumannii) (3.3%). Among the antimicrobial agents tested, the susceptibility rates of E.
coli to the two carbapenems, ertapenem and imipenem as well as amikacin and piperacillin-tazobactam ranged
from 92.5 to 98.7%. Against K. pneumonia, the most potent antibiotics were imipenem (92.6% susceptibility),
amikacin (89.2% susceptibility) and ertapenem (87.9% susceptibility).
Although non-Enterobacteriaceae did not show high susceptibilities to the 12 common antibiotics, amikacin
exhibited the highest in vitro activity against P. aeruginosa over the 5-year study period, followed by piperacillin-
tazobactam, imipenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin. The Extended Spectrum Beta-
Lactamase (ESBL) rates decreased slowly during the 5 years in E. coli from 68.6% in 2010 to 59.1% in 2014, in K.
pneumoniae from 59.7 to 49.2%, and in Proteus mirabilis (P. mirabilis) from 40.0 to 26.1%. However, the ESBL rates
were different in 5 regions of China (Northeast, North, East, South and Middle-China).
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Conclusion: E. coli and K. pneumonia were the major pathogens causing UTIs and carbapenems and amikacin
retained the highest susceptibility rates over the 5-year study period, indicating that they are good drug choices for
empirical therapies, particularly of CA UTIs in China.
Keywords: Urinary tract infections, Extended spectrum beta-lactamases (ESBLs), Carbapenems, Antimicrobial resistance
Background
Several national and international surveillance programs
have been initiated for monitoring susceptibilities of
clinically important pathogens in urinary tract infections
(UTIs) [1–3]. The Study for Monitoring Antimicrobial
Resistance Trends (SMART) is a surveillance program
designed to monitor globally susceptibilities of aerobic
and facultative Gram-negative bacilli collected from
intra-abdominal infections and UTIs (initiated in 2002)
[4]. UTIs are frequently encountered in clinical practice
and include uncomplicated and complicated pyeloneph-
ritis, ureteritis, cystitis and urethritis [5]. The etiologies
of these infections arise from Gram-negative bacilli, es-
pecially Enterobacteriaceae, and some Gram-positive
bacteria [6]. During the last decade, multidrug-resistant
Gram-negative Enterobacteriaceae have become a chal-
lenge for physicians [7] and particularly E. coli and K.
pneumonia strains isolated from UTIs have been re-
ported to increasingly produce ESBLs in the recent years
[8–10]. The choice of an empiric UTI antimicrobial
therapy should be based on knowledge of the pathogen
distribution and the resistance extent of common micro-
organisms, in addition to hospital-specific resistance pat-
terns particularly for HA infections. This study, as part
of the global SMART project, focused on ESBL-
producing rates of UTI isolates from 21 centers in 16
Chinese cities between 2010 and 2014 and on UTI de-
rived sample resistance rates against carbapenems, a
combination of drugs containing penicillins with β-
lactamase inhibitors, a cephamycin, an aminoglycoside,
3rd and 4thgeneration cephalosporins as well as 2nd gen-
eration fluoroquinolones, in order to provide guidance
for antimicrobial therapies of IAIs.
Methods
Clinical isolates
During our study period (2010–2014), a total of 4,332
aerobic and facultative Gram-negative bacilli were con-
secutively isolated from patients with UTIs in 21 hospi-
tals sited in 16 Chinese cities (Beijing, Shanghai,
Hangzhou, Nanjing, Shenyang, Tianjin, Wuhan, Changsha,
Jinan, Zhengzhou, Guangzhou, Nanchang, Haikou, Harbin,
Changchun and Chongqing).
All isolates were cultured from specimens collected
from patients who met both clinical and laboratory cri-
teria of urinary tract infections (3,994 from clean catch
midstream urine, 154 from urinary bladder, 136 from ur-
eter, 29 from kidney, 13 from urethra, 6 from prostate).
Duplicate isolates (same species and genus from one pa-
tient) were excluded.
Standard methods were used by the participating clin-
ical microbiology laboratories for initial bacteria identifi-
cation, and re-identification was carried out by a central
laboratory (Peking Union Medical College Hospital)
using Vitek 2 Compact (2010–2011) (Biomerieux,
France) and MALDI-TOF MS (2012–2014) (Vitek MS,
Biomerieux, France).
Isolates were considered to be community-associated
(CA) if they were recovered from a specimen taken less
than 48 h after the patient was admitted to a hospital,
and hospital-associated (HA) if the specimen was taken
48 or more hours after hospital admission, as previously
described [11].
Antimicrobial susceptibility test method
Minimum inhibitory concentration (MIC) determina-
tions were performed in a central lab using dehydrated
MicroScan broth microdilution panels (Siemens Medical
Solutions Diagnostics (West Sacramento, CA) according
to Clinical and Laboratory Standards Institute (CLSI)
guidelines [12] and susceptibility interpretations were
based on clinical CLSI breakpoints [13]. Twelve com-
monly used antimicrobial agents for UTI treatments
were analyzed namely, imipenem (IPM), ertapenem
(EPM), ceftriaxone (CRO), cefotaxime (CTX), ceftazi-
dime (CAZ), cefoxitin (FOX), cefepime (FEP),
piperacillin-tazobactam (TZP), ampicillin-sulbactam
(SAM), amikacin (AMK), ciprofloxacin (CIP) and levo-
floxacin (LVX). For each batch of MIC testing, the refer-
ence strains E. coli ATCC 25922, P. aeruginosa ATCC
27853 and K. pneumonia ATCC 700603 were used as
quality controls. Results were only included in the ana-
lysis when corresponding quality control isolate test re-
sults were in accordance with CLSI guidelines and
therefore within an acceptable range.
Extended-spectrum β-lactamases (ESBLs) detection
Phenotypic identification of ESBL production in E.coli, K.
pneumonia, Klebsiella oxytoca (K. oxytoca), and P. mirabilis
was carried out according to CLSI recommended methods
[13]. If cefotaxime or ceftazidime MICs were ≥ 2 μg/mL,
the MICs of cefotaxime + clavulanic acid (4 μg/mL) or
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ceftazidime + clavulanic acid (4 μg/mL) were comparatively
determined. ESBL production was defined as a ≥ 8-fold de-
crease in MICs for cefotaxime or ceftazidime tested in
combination with clavulanic acid, compared to their MICs
without clavulanic acid.
Statistical analysis
The susceptibility of all gram-negative isolates combined
was calculated using breakpoints appropriate for each spe-
cies and assuming 0% susceptible for species with no
breakpoints for any given drug. Ninety-five percent confi-
dence intervals were calculated using the adjusted Wald
method; linear trends of ESBL rates in different years were
assessed for statistical significance using the Cochran-
Armitage test and comparison of ESBL rates in 6 different
geographic areas were assessed using Chi-square test. P
values < 0.05 were considered statistically significant.
Results
Distribution of organisms from urinary tract infection
A total of 4,332 isolates were collected from UTIs between
2010 and 2014. The highest distribution of bacteria was E.
coli, which accounted for 63.2% (2,737 strains), followed
by K. pneumonia (12.2%, 529 strains) and P. aeruginosa
(6.9%, 297 strains) (Table 1). We also investigated the dis-
tribution of strains from HA (n = 2765, 72.16%) and CA
(n = 1039, 27.11%) (P < 0.0001) infections, but most of the
isolates were sampled from HA infections (62.59–80.42%)
(Table 1). Enterobacteriaceae were present in the majority
of isolates and accounted for 88.5%, including mainly
E.coli (63.2%), followed by K. pneumonia (12.2%), P. mir-
abilis (3.4%) and Enterobacter cloacae (E. cloacae) (3.3%),
while others were present at a rate < 1.3%. Non-Enterobac-
teriaceae accounted for only 11.5% of all isolates and
included mainly P. aeruginosa (6.9%) and Acinetobacter
baumannii (A. baumannii) (3.3%).
In vitro susceptibility of Enterobacteriaceae and non-
Enterobacteriaceae during 2010–2014
Among the 12 analyzed antimicrobial agents, the suscep-
tibility rates of ertapenem and imipenem against E. coli
over 5 years were 96.4% (2,639/2,737) and 98.7% (2,702/
2,737), with MIC90 values of 0.25 μg/mL for both drugs.
Most E.coli isolates remained susceptible to amikacin
(92.8%) and piperacillin-tazobactam (92.51%). However,
the susceptibilities to third- and fourth-generation ceph-
alosporins were relatively low, with rates of 58.5, 38.2,
34.6 and 34.4% for ceftazidime (CAZ), cefepime (FEP),
cefotaxime (CTX) and ceftriaxone (CRO), respectively.
The susceptibility rates of E. coli to fluoroquinolones
and ampicillin-sulbactam were also less than 30 and
20%, respectively (Fig. 1, Table 2).
Against K. pneumonia, the most potent antibiotics
were imipenem (92.6% susceptibility), amikacin (89.2%
susceptibility) and ertapenem (87.9% susceptibility), with
MIC90 values of 1 μg/mL, > 32 μg/mL and 1 μg/mL, re-
spectively. Piperacillin-tazobactam was the fourth most
active agent, with a susceptibility of 75.8%. The suscepti-
bility rates of other antibiotics ranged from 30.6% (ampi-
cillin-sulbactam) to 67.5% (cefoxitin) (Fig. 1, Table 2,).
Against P. mirabilis, antimicrobial agents with > 90%
susceptibility rates included ertapenem (99.3%),
piperacillin-tazobactam (99.3%) and amikacin (91.2%),
but in HA infections, a > 90% susceptibility rate was
found for ceftazidime (90.2%). Cephalosporin suscepti-
bility rates were 55.8–88.4% whereas fluoroquinolones
exhibited 41.5–55.1% activity. Imipenem had poor
Table 1 Distribution of the UTI pathogens in China between 2010 and 2014
Total CA (n/% of total) HA (n/% of total) Not identified (n/% of total) P-value
Enterobacteriaceae 3,832 1,039 (27.11) 2,765 (72.16) 28 (0.73) <0.0001
Escherichia coli 2,737 739 (27.00) 1,976 (72.20) 22 (0.80) <0.0001
Klebsiella pneumoniae 529 129 (24.39) 398 (75.24) 2 (0.38) <0.0001
Proteus mirabilis 147 54 (36.73) 92 (62.59) 1 (0.68) 0.011
Enterobacter cloacae 141 39 (27.66) 101 (71.63) 1 (0.71) <0.0001
Citrobacter freundii 54 11 (20.37) 43 (79.63) 0 (0.00) 0.0003
Klebsiella oxytoca 51 18 (35.29) 33 (64.71) 0 (0.00) 0.1205
other 173 49 (28.32) 122 (70.52) 2 (1.16) <0.0001
Non-Enterobacteriaceae 500 105 (21.00) 391 (78.2) 4 (0.8) <0.0001
Pseudomonas aeruginosa 297 65 (21.89) 231 (77.78) 1 (0.34) <0.0001
Acinetobacter baumannii 143 26 (18.18) 115 (80.42) 2 (1.40) <0.0001
other 60 14 (23.33) 45 (75.00) 1 (1.67) <0.0001
All 4,332 1,144 (26.41) 3,156 (72.85) 32 (0.74) <0.0001
Not identified: A total of 32 isolates lacked partial demographic information and could not be identified as CA or HA isolates. They were not included in
further analyses
Yang et al. BMC Infectious Diseases  (2017) 17:192 Page 3 of 9
activity against P. mirabilis isolates, with a mean suscep-
tibility rate of only 15.0% in both CA and HA derived
isolates (Figs. 1 and 2, Table 2).
Antimicrobial resistance in Enterobacter cloacae was
more pronounced than in E. coli and K. pneumonia. The
antimicrobial agents with susceptibility rates of > 80%
were amikacin (90.1%) and imipenem (85.1%) over the
5-year study period. Particularly in 2014, ertapenem and
piperacillin-tazobactam susceptibility rates in HA infec-
tions dropped to 53.9%, whereas CA UTIs were still
100% susceptible to both antibiotics (Fig. 2). However,
ertapenem was the third most active agent with suscepti-
bilities of 78.7% in all isolates, followed by piperacillin-
tazobactam (67.4%), levofloxacin (64.5%), ciprofloxacin
(56.7%) and cefepime (55.3%) (Fig. 1, Table 2).
Although non-Enterobacteriaceae did not show high sus-
ceptibilities to the 12 common antibiotics, amikacin exhib-
ited the highest in vitro activity against P. aeruginosa, with a
susceptibility rate of 84.2% over the 5-year study period,
followed by piperacillin-tazobactam, imipenem, ceftazidime,
cefepime, ciprofloxacin, and levofloxacin. (Figure 1, Table 2).
A. baumannii was the second most frequently isolated
non-fermentative Gram-negative bacillus, comprising
3.3% (143/4,332) of all UTIs. The most active agents
against A. baumannii were imipenem and amikacin, with
susceptibility rates of 46.9 and 46.2%, respectively over the
entire study period. The other analyzed agents were less
effective, with susceptibility rates of < 40% (Fig. 1, Table 2).
The trend of extended spectrum beta-lactamases (ESBL) –
producing bacteria occurrence in UTIs from 2010 to 2014
Figure 2a-c shows the frequency of ESBL-producing
E.coli, K. pneumonia, K. oxytoca and P. mirabilis strains
over the study period. The percentage of ESBL positive
E. coli isolates decreased from 68.6% in 2010 to 59.1% in
2014, while the ESBL rate in K. pneumonia decreased
from 59.7 to 49.2% and in P. mirabilis from 40.0 to
26.1% during the 5-year study period. The susceptibility
Fig. 1 Trends over time in the susceptibility of isolates from UTIs to antimicrobial agents in China. *EPM, ertapenem; IPM, imipenem; AMK, amikacin;
TZP, piperacillin-tazobactam; FOX, cefoxitin; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; LVX, levofloxacin; CIP, ciprofloxacin;
SAM, ampicillin-sulbactam. Note: The data of ETP FOX CRO and CTX susceptibilities for P. aeruginosa and ETP as well as FOX sensitivities
for A. baumannii were not shown because of lack of corresponding breakpoints
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differences to ertapenem and imipenem between ESBL
and non-ESBL producing strains were generally small, but
were greater for other agents, particularly for the third-
and fourth-generation cephalosporins, including ceftriax-
one (1.1% against ESBL-producing isolates vs 91.0%
against ESBL-non-producing isolates), ceftazidime (38.4%
vs 93.5%) and cefepime (4.5% vs 96.7%) (data not shown).
Figure 2d-e shows the ESBL rates in E. coli, K. pneu-
monia, and P. mirabilis from UTIs in different regions
in China. We categorized the 21 participating sites into
5 different regions in China (Northeast (Haerbin,
Changchun and Shenyang), North (Beijing and Tianjing),
East (Hangzhou, Nanjing, Jinan, Nanchang and Shang-
hai), South (Chongqing, Guangzhou and Haikou) and
Central China (Changsha, Zhengzhou and Wuhan)).
The two sites in the Central China region exhibited
higher ESBL rates in E. coli (81.5%) and K. pneumonia
(64.9%), while other regions showed relatively lower
ESBL rates in these two species (54.5–65.1% for E. coli,
and 48.1–56.3% for K. pneumoniae). For P. mirabilis, the
ESBL rates ranged from 31.4% (South China region) to
47.5% (North China region).
Discussion
Nitrofurantoin, trimethoprim-sulfamethoxazole, fosfo-
mycin, fluoroquinolones and beta-lactams are commonly
recommended antimicrobial agents for urinary tract in-
fections [14]. However, fosfomycin and nitrofurantoin
are not often used in China [2]. The usage of
trimethoprim-sulfamethoxazole for the treatment of
UTIs in China is also limited because of a high resist-
ance rate to this agent among E.coli isolates [15]. In view
of this finding, we focused on the activity of beta-
lactams, fluoroquinolones and aminoglycoside against
uropathogens in the present study. Since Enterobacteria-
ceae accounted for the majority of aerobic and faculta-
tive anaerobic pathogens causing UTIs (88.5% of all
isolates) in our study, with E.coli, K. pneumonia, P. mir-
abilis and Enterobacter cloacae the most frequently iso-
lated species, knowledge of their resistance pattern is
beneficial.
Cephalosporins are commonly recommended as em-
pirical choices for UTIs, but their efficacy is greatly re-
duced when the pathogens produce ESBL. Over the
entire study period, susceptibility rates of Enterobacteri-
aceae to third-generation and fourth-generation cepha-
losporins were 51.4–66.0% for ceftazidime, 29.4–46.9%
for cefotaxime, 29.9–41.2% for ceftriaxone and 35.1–
47.1% for cefepime, indicating that these agents might
not be the optimum medications for empirical UTI ther-
apies. In the present study, the percentage of ESBL posi-
tive E. coli isolates decreased from 66.9% in 2010 to
59.1% in 2014, while for K. pneumonia it decreased from
59.7 to 48.8% and from 40.0 to 26.1% among P. mir-
abilis. The data were well matched with the non-
susceptibility rates to cephalosporins against each
species, which indicated that ESBL production might be
a reason for cephalosporin resistance [16]. The decrease
of ESBL rates in E. coli, K. pneumonia and P. mirabilis
may have been a result of China’s antimicrobial steward-
ship policy on antimicrobial use, which has been pro-
moted for a number of years [17–19]. Our study also
highlighted the variation in ESBL rates in different re-
gions of China, with the Central-China region having a
higher ESBL prevalence in E. coli and K. pneumonia. Re-
searchers previously reported that the ESBL genotypes
in China were mainly CTX-M types [20–22], especially
CTX-M-14, −15, and −55 for E. coli and K. pneumonia,
and CTX-M-65 and −14 for P. mirabilis [22]. Plasmids
encoding these CTX-M enzymes reached human oppor-
tunists, where they have proliferated in community E. coli
and hospital K. species. CTX-M families are dominate in
different regions: CTX-M-15 is predominant in most of
Europe, North America, the Middle East, and India, but






Escherichia coli IPM 98.72 0.12 0.25
ETP 96.42 ≤0.03 0.25
AMK 92.88 ≤4 16
TZP 92.51 ≤2 16
Klebsiella pneumoniae IPM 92.63 0.25 1
AMK 89.22 ≤4 >32
ETP 87.9 ≤0.03 1
TZP 75.8 ≤2 >64
Proteus mirabilis ETP 99.32 ≤0.03 0.06
TZP 99.32 ≤2 4
AMK 91.16 8 16
CAZ 88.44 ≤0.5 8
Enterobacter cloacae AMK 90.07 ≤4 16
IPM 85.11 0.5 2
ETP 78.72 0.12 4
TZP 67.38 4 >64
Pseudomonas aeruginosa AMK 84.18 8 >32
TZP 76.43 4 >64
IPM 74.75 1 >8
CAZ 74.41 4 64
Acinetobacter baumannii IPM 46.85 8 >8
AMK 46.15 >32 >32
LVX 36.36 >4 >4
CAZ 34.27 64 >128
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CTX-M-14 is most common in China, Southeast Asia and
Spain, while CTX-M-2 is predominant in Argentina,
Israel, and Japan [23, 24]. Increased numbers of enzyme
types and prevalence made determination of resistance
profiles more complicated.
Fluoroquinolones, especially ciprofloxacin and levo-
floxacin, were considered to be effective antimicrobial
agents against uropathogens because of high drug
concentrations are reached in the urine. However,
fluoroquinolone-resistant E. coli is also problematic in
China. The susceptibility of E. coli to fluoroquino-
lones (ciprofloxacin and levofloxacin) was 26.9–28.9%,
with rates of 30.2–32.1% against CA isolates and
25.7–27.8% against HA isolates. Wang et al. also pre-
viously reported about ciprofloxacin-resistant E. coli
strains with multiple gyrA and parC gene substitu-
tions [25]. Regarding the low effectiveness of fluoro-
quinolones against Enterobacteriaceae, ciprofloxacin
and levofloxacin should not be considered as first line
agents for empirical therapies of complicated UTIs.
Our data also showed that susceptibilities of ESBL-
producing E. coli and K. pneumonia strains to fluoro-
quinolones were significantly lower than that of
ESBL-non-producing strains, which is in agreement
with previous findings [26].
Carbapenems can still be considered to be suitable for
severe infections and as alternative empiric treatment
for UTIs caused by bacterial strains highly suspicious of
being ESBL-producing or AmpC-derepressed Enterobac-
teriaceae [27–29]. Although carbapenems were not the
first line choices for uncomplicated cystitis and pyelo-
nephritis in women according to the IDSA guideline,
they were good alternatives against multidrug resistant
Gram-negative bacilli that caused UTIs. Our study
showed that ertapenem and imipenem were the most ef-
fective agents against Enterobacteriaceae causing UTIs,
with susceptibility rates of 92.5–96.5% and 89.9–95.2%,
respectively (2010–2014). On the other hand,
carbapenem-resistant Enterobacteriaceae have emerged,
which has also been noted in other reports [30–33], es-
pecially KPC-producing K. pneumonia in the north-
eastern area of the United States of America [31], KPC/
VIM-producing Enterobacteriaceae in Greece [32, 33]
and KPC-producing isolates in eastern China. In our
study, very few E. coli isolates (<4%) were non-
susceptible to carbapenems, while there was a certain
proportion of carbapenem-non-susceptible K. pneumo-
nia isolates (13.8% to ertapenem), P. mirabilis (85% to
imipenem) and E. cloacae (21.3% to ertapenem and
14.9% to imipenem), which should be noted by
Fig. 2 ESBL rate of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis from UTIs in different regions and years in China (SMART 2010–2014). a-c
ESBL rates of all samples, b ESBL rates of HA UTI isolates, c ESBL rates of CA UTIs. d ESBL rates of all samples, e HA UTI isolates and f CA UTI isolates
collected between 2010 and 2014 in the indicated Chinese regions. * P < 0.05; ** P < 0.01
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clinicians. Especially for E. cloacae the susceptibility of
HA samples to ertapenem has dropped to 53.9%, while
for CA UTIs its susceptibility rate is 100%. Hospital in-
fections caused by E. cloacae, which is a typical com-
mensal under normal conditions, have been suggested to
be mainly caused by endogenous translocation from the
digestive tract in debilitated patients and that under
antibiotic therapy, E. cloacae strains may selectively re-
produce excessively in the gastrointestinal tract [34].
This might be the reason for the high ertapenem resist-
ance in UTIs mainly caused by HA E. cloacae. The main
resistance mechanism to carbapenem in Enterobacteria-
ceae was reported to be carbapenemase production and
porin loss in China [35]. However, the resistance of P.
mirabilis to imipenem was caused by a mechanism other
than carbapenemase [13].
Among the tested antimicrobial agents, amikacin exhib-
ited good activity against most of the uropathogens (80.0–
96.2% susceptibility rate against Enterobacteriaceae and
83.6% against P. aeruginosa). Although the use of this
aminoglycoside is limited because of its toxicity, it has also
been recommended as an alternative to carbapenems
against ESBL-producing isolates that cause UTIs [36].
Conclusion
Carbapenems remain the most effective antimicrobial
agents against UTI Gram-negative pathogens, followed
by amikacin and piperacillin-tazobactam in China be-
tween 2010 and 2014. Due to the reduced susceptibility
of Enterobacteriaceae to cephalosporins and fluoroqui-
nolones, we recommend that these antibiotics should
not be used for empirical UTI therapies in China.
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Fig. 3 Trends over time in the susceptibility of isolates from UTIs to antimicrobial agents in China (CA and HA). *EPM, ertapenem; IPM, imipenem;
AMK, amikacin; TZP, piperacillin-tazobactam; FOX, cefoxitin; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; LVX, levofloxacin;
CIP, ciprofloxacin; SAM, ampicillin-sulbactam. Note: The data of ETP FOX CRO and CTX susceptibilities for P. aeruginosa and ETP as well as FOX
sensitivities for A. baumannii were not shown because of lack of corresponding breakpoints
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